GNS Healthcare Blog

GNS Healthcare Blog

GNS Healthcare Primary Blog

By December 31, 1969

Can Personalized Medicine Be the Answer to Value-based Care?

There's been a lot of conversation around value-based care (VBC) models, and payers, providers and biopharma – each have their own take on what VBC means to them. But lately there has been more conversation around patient-centered care and what that looks like through the lens of a value-based approach.

Value-based care – paying for outcomes as opposed to a fee for service or procedure – has been growing in recent years. A recent report found that the percentage of healthcare payments tied to value-based care reached 34 percent in 2017, up 23 percent from 2015, and affecting approximately...

Read More

The Boston Marathon and AI: Running a Parallel Course

 In 1896, the marathon returned to popularity as a competition in the Summer Olympic Games in Athens. The Olympic Games turned out to be inspiring to visiting Boston officials who returned home ready to challenge the locals and establish what would become one of the world’s top marathons.[1] Next Monday, April 15th, 30,000 runners will hit the road in what will be the 123rd Boston Marathon.

Across the Charles River and throughout the U.S. another race is being run, the race to bring artificial intelligence (AI) to the world of healthcare. So what does a long running (pun intended) marathon...

Read More

Biomarkers: The Guideposts for Drug Discovery and Development

Biomarker-guided precision medicine is increasingly important in drug discovery and development. Pharma products that incorporate biomarkers to support optimized trial design and selection criteria are three times more likely to make it from Phase I to FDA approval than those  that do not.[1] Clinical trials that leverage biomarkers for patient stratification to guide their inclusion and exclusion criteria made up about 34% of oncology studies in 2017.[2] Clinical trials costs are also affected by biomarker-driven development. Equally impactful, one study notes that the use of a validated...

Read More

Hypothesis Free AI: Discovering the Insights We Didn't Know to Ask

 

Much research and analysis in healthcare is based on testing preconceived hypotheses – looking to  answer a narrow set of questions in the form of a hypothesis. Traditional statistical analyses begin with an explicit hypothesis – a specific statement of how variables interact to explain an observation or phenomenon – which is then statistically tested to confirm whether or not the data supports that position.

Artificial Intelligence (AI) is increasingly being used to carry out this type of healthcare testing from drug discovery to targeted interventions at the point of care. We have seen...

Read More

Celebrating International Women’s Day: Healthcare Innovators

Tomorrow, March 8th, is International Women’s Day. While a public holiday in just a few countries, it is a day to celebrate the success and power of women from gaining suffrage to working their way into the board room. As such, we wanted to recognize some of the women in healthcare (and take it from us we could have featured hundreds if we had the room) who are leaders in their fields and driving innovation within their respective organizations, and healthcare as a whole.

Read More

Lowering Barriers: How Real-World Data and AI Is Transforming Drug Market Access Strategy

This is the third in a three-part series on the impact of AI on the product development life cycle of drugs from discovery, to clinical trials and market access.  

 

Regulatory approval of a drug does not immediately translate into premier market access or projected results. The reality is that the pressure on pharma companies from health plans and pharmacy benefit managers (PBMs) to provide evidence-based research on treatment efficacy and effectiveness before including drugs on their formularies is only increasing.

The earlier pharma companies can answer these asks, the better. The goal...

Read More

The New World of Drug Development: Transforming Clinical Trials with AI

The following is the second in a three-part series on the impact of AI on the product development life cycle of drugs from discovery, to clinical trials and market access.

 

The success of clinical trials relies heavily on having enough of the right patients willing and able to participate. Unfortunately, achieving the levels of recruitment necessary to conduct successful trials is difficult – particularly in cancer and rare diseases trials.

One recent survey revealed that only one in three cancer patients were likely to enroll in a clinical trial. Less than half of those surveyed viewed...

Read More

Drug Discovery and AI: An Unlikely Marriage or Perfect Partners?

The following is the first in a three-part series on the impact of AI on the product development life cycle of drugs from discovery, to clinical trials and market access.

 

Biopharma companies and government funded research projects have produced stellar results over the years: from lifesaving drugs and to life improving therapies that benefit millions of patients. But these discoveries often come at a substantial financial cost and take many years to bring to market. In fact, the cost of bringing one drug from discovery to approval is currently estimated at between $1.8 and $3.0 billion....

Read More

Follow the Tumor: How Oncology R&D is Leading the Charge in AI Implementation

 

In 2017, the American Cancer Society awarded $112 million for cancer research.[1] The National Institute of Health FY17 budget for cancer research was nearly $6 billion.[2]

Pharma companies are pouring billions of R&D dollars into developing new treatments for cancer and are looking for the best ways to maximize those investments. One of the, most effective research tools available and one increasingly leveraged by biopharma is artificial intelligence (AI), used to help unlock the complex mechanisms of cancer.

Oncology is an enormously complicated field, so it’s no surprise that...

Read More

Revisiting 2018 Healthcare Predictions: 5 That Got It Right

The new year has just begun and the flurry of predictions for 2019 are popping up everywhere. Healthcare thought leaders have joined in offering their forecasts and ruminations around what we can expect over the next 12 months. We did the same and asked prominent thought leaders to offer their opinions in our prediction post earlier this year.

But what about the predictions made a year ago? How did the 2018 predictions actually turn out and what will continue into 2019? 

We took a look back to see what we could find. As expected, there were hits and misses but there were five that were on...

Read More

Subscribe to the GNS Blog

Recent Posts:

Twitter